8-K: Nu-Med Plus Acquisition of YourSpace America Terminated, CEO Resigns

Nu-Med Plus, Inc. has terminated its acquisition agreement with YourSpace America, Inc. due to the failure of YourSpace to provide audited financial statements, leading to the resignation of the appointed CEO and the appointment of the Chairman as the new CEO.

Summary

• Nu-Med Plus, Inc. had entered into a Share Exchange Agreement with YourSpace America, Inc. on April 28, 2024, where Nu-Med would acquire all of YourSpace's stock.
• The agreement was contingent on YourSpace providing audited financial statements for the years 2021, 2022, and 2023.
• YourSpace provided audited financials for 2021 and 2022, but failed to provide the 2023 statements.
• Due to the missing 2023 audited financials, Nu-Med could not issue stock to YourSpace or its principals.
• On October 28, 2024, YourSpace terminated the acquisition agreement.
• The planned stock issuance did not occur, and therefore there was no change in control of Nu-Med Plus.
• Russ Colvin, who was appointed as President/CEO and Director in anticipation of the acquisition, resigned from his positions.
• William Hayde, the Chairman of the Board, was appointed as the new President/CEO on October 28, 2024.

Sentiment

Score: 3

Explanation: The document reflects a negative event with the termination of an acquisition and a change in leadership, indicating a setback for the company.

Positives

• The company avoided a potentially problematic acquisition due to the lack of financial transparency from YourSpace.
• The company quickly appointed a new CEO from within the existing leadership team, ensuring continuity.

Negatives

• The termination of the acquisition agreement represents a setback for Nu-Med Plus's growth strategy.
• The resignation of the appointed CEO creates a period of transition and uncertainty.

Risks

• The failure of YourSpace to provide audited financial statements raises concerns about their financial health and transparency.
• The terminated acquisition may impact investor confidence in Nu-Med Plus's ability to execute its strategic plans.
• The change in leadership could lead to a period of instability and potential strategic shifts.

Future Outlook

The document does not provide any specific forward-looking statements or guidance.

Management Comments

• Mr. Russ Colvin was appointed to be the President/Chief Executive Officer and a Director of Nu-Med, fully expecting the terms of the agreement to be met.
• Mr. Colvin submitted his resignation from the positions to which he had been appointed.
• The Board of Directors appointed Mr. William Hayde to serve as President/Chief Executive Officer of Nu-Med.

Industry Context

The termination of the acquisition agreement highlights the importance of due diligence and financial transparency in mergers and acquisitions. It is not uncommon for deals to fall through due to issues with financial reporting.

Comparison to Industry Standards

• The failure to provide audited financial statements is a significant red flag in any acquisition process, and it is not uncommon for deals to be terminated due to such issues.
• The quick appointment of a new CEO from within the existing leadership team is a common practice to ensure stability during transitions.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the failed acquisition and the change in leadership.
• Employees may experience uncertainty due to the leadership change.

Key Dates

Keywords

acquisition, merger, share exchange, financial statements, CEO, resignation, corporate governance, leadership change